Updating results

323 results for template

Sort: Date | Relevance

Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of overt hepatic encephalopathy

Technology appraisal guidance Published March 2015

Alcohol: preventing harmful use in the community (QS83)

This quality standard covers preventing and identifying alcohol problems in the community. It includes policy and practice approaches to prevent harmful alcohol use in adults, young people and children. It is particularly relevant to local authorities, the police, and schools and colleges. It describes high-quality care in priority areas for improvement.

Quality standard Published March 2015

Obesity prevention (CG43)

This guideline covers preventing children, young people and adults becoming overweight or obese. It outlines how the NHS, local authorities, early years’ settings, schools and workplaces can increase physical activity levels and make dietary improvements among their target populations.

Clinical guideline Published December 2006 Last updated March 2015

Sofosbuvir for treating chronic hepatitis C (TA330)

Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

Technology appraisal guidance Published February 2015

Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

Evidence-based recommendations on vemurafenib (Zelboraf) for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma

Technology appraisal guidance Published December 2012 Last updated January 2015

The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

Advice on the use of Oncentra Prostate v4.x for ultrasound-guided real-time HDR brachytherapy in men with localised prostate cancer to aid local decision-making

Medtech innovation briefing Published December 2014

Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence

Technology appraisal guidance Published November 2014

Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

Evidence-recommendations on erythropoiesis-stimulation agents (epoetin alfa, beta, theta and zeta and darbepoetin alfa) for anaemia in people with cancer..

Technology appraisal guidance Published November 2014

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA326)

Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)

Technology appraisal guidance Published November 2014

Interim methods guide for developing good practice guidance (PMG15)

Interim methods guide for developing good practice guidance

Published September 2014 Last updated September 2014

Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320)

Evidence-based recommendations on dimethyl fumarate (Tecfidera) for treating relapsing-remitting multiple sclerosis (MS/RRMS)

Technology appraisal guidance Published August 2014

Fever in under 5s (QS64)

This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement.

Quality standard Published July 2014

Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

Evidence-based recommendations on ipilimumab (YERVOY) for treating previously untreated advanced (unresectable or metastatic) melanoma (skin cancer)

Technology appraisal guidance Published July 2014

Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

Technology appraisal guidance Published June 2014

Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes

Technology appraisal guidance Published June 2014

Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults

Technology appraisal guidance Published January 2014 Last updated June 2014

Alemtuzumab for treating relapsing‑remitting multiple sclerosis (TA312)

Evidence-based recommendations on alemtuzumab (Lemtrada) for treating active relapsing–remitting multiple sclerosis (MS)

Technology appraisal guidance Published May 2014

Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..

Technology appraisal guidance Published April 2014

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

Technology appraisal guidance Published February 2014

Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)

Evidence-based recommendations on pixantrone (Pixuvri) for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma

Technology appraisal guidance Published February 2014

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy

Technology appraisal guidance Published November 2013

Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

Technology appraisal guidance Published August 2006 Last updated November 2013

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration

Technology appraisal guidance Published July 2013

Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction (IPG457)

Evidence-based recommendations on inserting customised exposed titanium implants, (without soft tissue cover) for complex orofacial (face) reconstruction

Interventional procedures guidance Published July 2013

Measures to improve the care for people who self-harm

The number of people who self-harm has risen steadily over the past two decades, meaning the UK now has one of the highest rates in Europe.

News Published July 2013 Last updated July 2013

Insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction (IPG449)

Evidence-based recommendations on insertion of customised titanium implants, with soft tissue cover for orofacial (face and jaw) reconstruction

Interventional procedures guidance Published March 2013 Last updated July 2013

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Symptom relief key for common 'distressing' bowel condition

Symptom relief through the range of recommended drugs and treatments available should be the primary outcome for patients with ulcerative colitis, according to NICE.

News Published June 2013 Last updated June 2013

Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published May 2013

Prompt diagnosis of social anxiety disorder leads to effective treatment

A prompt diagnosis of social anxiety disorder is crucial in ensuring people access the most clinical and cost effective treatment, according to NICE.

News Published May 2013 Last updated May 2013

Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)

Medicines optimisation: key therapeutic topics – Integrated process statement

Published May 2013 Last updated May 2013

Guide to the methods of technology appraisal 2013 (PMG9)

Guide to the methods of technology appraisal 2013

Published April 2013 Last updated April 2013

Offer calcium-based phosphate binders to manage hyperphosphataemia, says NICE

Adults with hyperphosphataemia in chronic kidney disease should be offered a calcium-based phosphate binder as a first-line treatment in addition to dietary management, says NICE.

News Published March 2013 Last updated March 2013

Epilepsy in children and young people (QS27)

This quality standard covers diagnosing, treating and managing epilepsy and seizures in children and young people (under 18). It describes high-quality care in priority areas for improvement.

Quality standard Published February 2013

Epilepsy in adults (QS26)

This quality standard covers diagnosing, treating and managing epilepsy and seizures in adults (aged 18 and older). It describes high-quality care in priority areas for improvement.

Quality standard Published February 2013

Ranibizumab for treating diabetic macular oedema (TA274)

Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema

Technology appraisal guidance Published February 2013

Key therapeutic topics – Medicines management options for local implementation: Interim process statement (PMG7)

Key therapeutic topics – Medicines management options for local implementation: Interim process statement

Published January 2013 Last updated January 2013

WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension (MTG13)

Evidence-based recommendations on the WatchBP Home A for opportunistically detecting atrial fibrillation (AF) when diagnosing and managing hypertension

Medical technologies guidance Published January 2013

Greater awareness of hepatitis B and C needed

Greater awareness of hepatitis B and C is needed so that more people who are at risk can be tested and treated for the viruses, according to latest guidance from NICE.

News Published December 2012 Last updated December 2012

Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)

Technology appraisal guidance Published August 2010 Last updated December 2012

Tackle obesity through a 'community-wide'approach

Obesity should be tackled by encouraging different organisations to work together through a 'community-wide' approach, according to latest guidance from NICE.

News Published November 2012 Last updated November 2012

Ivabradine for treating chronic heart failure (TA267)

Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure

Technology appraisal guidance Published November 2012

Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)

Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours

Technology appraisal guidance Published October 2012

Alteplase for treating acute ischaemic stroke (TA264)

Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)

Technology appraisal guidance Published September 2012

NICE outlines options for assessing fragility fracture risk

GPs should use either the FRAX or QFracture tools to estimate fracture risk in at-risk patients, NICE says.

News Published August 2012 Last updated August 2012